Bioavailability of Ubiquinol in Huntington Disease

The death of brain cells in Huntington Disease (HD) is thought to be associated with a lack of normal cell energy and harmful brain substances called free radicals. Coenzyme Q10 (CoQ) is a marketed nutritional supplement that may prove useful in HD because it increases cell energy and combats free radicals.

Most studies of CoQ have looked at only one formulation of CoQ ("ubiquinone") in HD. The purpose of the study is to find out if people that switch from the common formulation of CoQ ("ubiquinone") to a different formulation ("ubiquinol") have higher levels of CoQ in their blood after taking the same dose. The investigators also want to find out if this different formulation is tolerable for individuals with HD.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Huntington Disease Basal Ganglia Diseases Brain Diseases Central Nervous System Diseases Chorea Cognition Disorders Congenital, Hereditary, and Neonatal Diseases and Abnormalities Dementia Dyskinesias Genetic Diseases, Inborn Heredodegenerative Disorders, Nervous System Mental Disorders Movement Disorders Nervous System Diseases Neurocognitive Disorders Neurodegenerative Diseases

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 1

Primary location

University of Rochester

Rochester, New York, 14618, United States

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Have manifest Huntington disease
Be 18 years of age or older
Be taking an oxidized formulation of CoQ for at least 30 days prior to the baseline visit
Be on a steady dose of all concomitant medications for at least 30 days prior to the baseline visit

Exclusion criteria

Have a history of intolerability of sensitivity to CoQ
Have an unstable medical or psychiatric illness
Be pregnant or breastfeeding; women of childbearing age must use reliable contraception

Treatment and study plan

ubiquinol

Dietary Supplement

up to 600 mg per day, oral capsules for 8 weeks

Primary outcomes

serum coenzyme Q10 levels

Time frame: 8 weeks

Sponsors and collaborators

Lead sponsor

University of Rochester

Other

Collaborators

Kaneka Corporation

Registry information

Important dates

Study start: 2009
Primary completion: 2012
Study completion: 2012
First posted: Sep 21, 2009
Registry last updated: May 27, 2016

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed